GleamWall
中文EN

ATRA Atara Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%

Returns

ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.22M$630,000$516,000$1.59M$3.45M$17.57M$98.15M$32.75M
Cost of revenue$265,000———$115,000———
Gross profit$959,000———$3.34M———
R&D expense$1.10M$1.34M$164,000-$223,000$2.92M$7.31M$27.43M$28.72M
SG&A expense$2.83M$3.81M$3.60M$4.28M$3.99M$6.51M$11.47M$9.44M
Operating income-$2.97M-$4.72M-$3.37M-$2.56M-$3.57M$3.20M$38.80M-$12.20M
Interest expense—$191,000$830,000$894,000$909,000$972,000$1.02M$1.02M
Pretax income-$2.23M-$4.83M-$4.14M-$3.41M-$4.28M$2.39M$38.01M-$12.71M
Income tax$0$1,000$0$0$28,000$3,000$0-$19,000
Net income-$2.23M-$4.83M-$4.14M-$3.41M-$4.30M$2.39M$38.01M-$12.69M
EBITDA-$2.97M-$4.71M-$3.34M-$2.51M-$3.54M$3.43M$40.60M-$11.10M
EPS (basic)-0.15-0.32-0.29—-0.320.203.53—
EPS (diluted)-0.15-0.32-0.29—-0.320.193.50—
Weighted avg. shares (diluted)15.33M15.03M14.08M—13.56M12.31M10.85M—
Balance sheet
Cash & equivalents$4.05M$3.22M$8.36M$8.48M$5.74M$16.90M$13.99M$25.18M
Short-term investments$5.86M$6.65M—$0$7.97M$5.42M$0$17.47M
Receivables$691,000$318,000$0$1.25M$1.91M$0$8.88M$1.48M
Inventory———$0$0$0$0$10.65M
Current assets$11.31M$13.53M$12.17M$12.21M$18.43M$24.77M$27.18M$64.89M
PP&E, net$38,000$41,000$55,000$73,000$147,000$176,000$285,000$1.29M
Total assets$18.61M$21.02M$20.00M$20.23M$30.17M$36.90M$62.04M$109.10M
Current liabilities$6.57M$6.85M$5.64M$14.92M$18.06M$14.56M$47.89M$134.57M
Total liabilities$56.51M$58.02M$57.31M$58.74M$66.80M$71.94M$117.11M$206.38M
Shareholders' equity-$37.90M-$37.00M-$37.31M-$38.50M-$36.63M-$35.04M-$55.07M-$97.28M
Shares outstanding10.19M9.44M8.51M7.32M7.21M6.98M5.92M5.86M
Cash flow statement
Operating cash flow-$879,000-$3.34M-$3.07M-$5.70M-$9.79M-$7.32M-$28.14M-$24.47M
Capital expenditure———$0$0$0$0$90,000
Free cash flow———-$5.70M-$9.79M-$7.32M-$28.14M-$24.56M
Investing cash flow$833,000-$6.63M$0$8.44M-$2.42M-$5.07M$17.20M$3.38M
Financing cash flow$880,000$4.83M$2.95M-$3,000$1.05M$15.30M-$250,000-$328,000
Depreciation & amortization$3,000$14,000$29,000$49,000$36,000$236,000$1.79M$1.10M
Stock-based compensation$457,000$394,000$749,000$1.52M$1.23M$2.80M$4.21M$5.85M

Free plan shows the latest 8 periods; Pro shows all 53 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.